Page 2 - கியூசெப் எஸ்போசிட்டோ News Today : Breaking News, Live Updates & Top Stories | Vimarsana

On April 12, 2021, Sequentia Biotech, a Spanish omics company, and NextBiomics, a biotech company involved in the research and development of Next Generation Probiotics and a spin-off of the Federico II University of Naples, announced the filing of a patent application for a bacterial vaccine against the COVID-19 syndrome. By engineering the probiotic Escherichia Coli Nissle 1917 expressing the SARS-CoV-2 Spike protein, it was possible to obtain an innovative model of immunization against COVID-19 by stimulating the intestinal immune system”, Giovanni Sarnelli “The NEXBIOMICS vaccine is similar to others that have been already authorized (Pfizer, Moderna, AstraZeneca, Reithera, Johnson & Johnson) in that it stimulates the immune response against the Spike protein that the Coronavirus uses to infect cells, but it differs from them because it uses a probiotic bacterium as a vector, which is already on the market and being widely used for other purposes.

Walter sanseverinoSequentia biotechmayFrancesco campobassoGiuseppe espositoGiovanni sarnelliUniversity of naples federicoSapienza university of romeFederico ii university of naplesFrom sequentia biotechmaySequentia biotechNext generation probioticsEscherichia coli nissleSapienza universityNew generation probioticsNaples federicoImmune response